about

Empowering our partners’ drug discovery to make better medicine

Services

Work with us across several modalities with various offerings and a flexible partnering approach

Our story

For years, Alloy has been changing the way drugs get to market

With 100% of our profits invested into future innovation, we are continuously pushing the boundaries of science to deliver groundbreaking solutions. With every project, we strive to refine our technologies, explore new possibilities, and empower our partners to transform ideas into impactful breakthroughs

2017

Founding year

2018

ATX License available. First Partnership signed.

2019

Cambridge UK lab opens

2020

Antibody Discovery services available

2021

Expands discovery AI/ML capabilities with DeepCDR acquisition

2022

Anticlastic technology & Genetic Medicine offerings available

2023

CLC platforms available for bispecifics

2024

iPSCs CAR-T technology & cell thereapies offerings available

Driving Innovation with our Global Footprint

Alloy’s 100+ scientists bring deep and diverse expertise to tackle your hardest projects. Headquartered in Waltham, MA, our global teams include high velocity antibody discovery in Athens, GA, transgenic platform development in Cambridge, UK, and our computational biology team in Basel, CH.

Committed to supporting your career and growth goals, here and throughout our ecosystem.

Fostering a supportive environment of diversity and inclusion where our team members and colleagues can share a wide range of perspectives that create an environment where innovation happens and people can do their best work.